Amarantus Bioscience Holdings, Stock Price - AMBS

Best deals to access real time data!
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Amarantus Bioscience Holdings, Inc. (PC) AMBS Other OTC Common Stock Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  +0.002 +9.09% 0.024 0.0249 0.0202 0.022 0.022 16:54:02
Bid Price Ask Price Spread Spread % News
0.0001 0.026 0.0259 99.62% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
30 324,336 $ 0.0222 $ 7.19k 325.48k 0.02 - 0.21
Last Trade Time Type Quantity Stock Price Currency
15:58:06 1,000 $0.02 USD

Amarantus Bioscience Holdings, Inc. (PC) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 5.62M 234.16M $ -25.21M - -0.22 75.96M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Amarantus Bioscience Holdings, Inc. (PC) News

Latest AMBS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AMBS Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.023450.0307550.021750.0253376k679k501k0.000552.35%
1 Month0.02030.0307550.020.0241741M380k0.003718.23%
3 Months0.030.037420.020.0267741M334k-0.006-20.00%
6 Months0.0540.0540.020.0344742M461k-0.03-55.56%
1 Year0.04450.20850.020.0600749M667k-0.0205-46.07%
3 Years0.720.720.010.08037414M604k-0.696-96.67%
5 Years78.10.010.14277414M549k-6.976-99.66%

Amarantus Bioscience Holdings, Inc. (PC) Description

Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. AMBS also owns approximately 79.25 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.